Antonio Giovanni Solimando¹*, Giuseppe Di Lernia¹, Sebastiano Cicco¹, Patrizia Leone¹, Roberto Ria¹, Vito Racanelli¹, Christoph Köchel², Daniel Gundel², Angelo Vacca¹ and Hermann Einsele²

¹Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine “G. Baccelli”, University of Bari Medical School, Bari, Italy
²Medical Clinic and Polyclinic II, University Hospital Würzburg, Würzburg, Germany

*Corresponding Author: Antonio Giovanni Solimando, Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine “G. Baccelli”, University of Bari Medical School, Policlinico, Bari, Italy.

Received: December 29, 2017; Published: January 19, 2018

Citation: Antonio Giovanni Solimando., et al. “First-Line Therapy in the Transplant Candidate Multiple Myeloma Patient: Short Clinical Review”. Acta Scientific Pharmaceutical Sciences 2.2 (2018).

Abstract

  The current therapeutic paradigm for the transplant recipient in multiple myeloma needs to be continuously updated. It will be clarified if it actually defines the standard of care stating the unmet needs as well. With the dual purpose of treating a symptomatic disease and obtaining a maximized depth of response autologous stem cell support (ASCT) is the backbone of young multiple myeloma patient approach. This manuscript provides a real-life oriented strategy, needed for a patient centered clinical practice.

Keywords: Transplant; Multiple Myeloma; Autologous Stem Cell Support (ASCT)

Copyright: © 2018 Antonio Giovanni Solimando., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.